IPO Tracker

Maharashtra State Electricity Distribution Company Limited (MSEDCL) is reportedly planning an Initial Public Offering (IPO) to raise between ₹4,150 crore and ₹8,300 crore, potentially marking a significant shift for India's power distribution sector and offering a rare investment opportunity.

Adisoft Technologies' Initial Public Offering (IPO) opened to strong investor interest, achieving an oversubscription of 1.45 times on its first day of bidding, driven primarily by Qualified Institutional Buyers (QIBs).

Leapfrog Engineering Services' Initial Public Offering (IPO) is now open for subscription, aiming to raise ₹88.51 crore. This SME IPO offers shares in a price band of ₹21-23.

Adisoft Technologies, a player in industrial digital automation, has launched its ₹74 crore SME IPO, aiming to fund a new manufacturing facility amid robust revenue growth.

The Mehul Telecom IPO allotment is set for finalization today, April 22. Investors can check their status on Kfin Technologies, with shares credited from April 23 for successful applicants.

SEBI has granted approval to six companies spanning renewable energy, chemicals, and SaaS sectors to launch their initial public offerings. The approvals signal continued investor interest in India's primary market.

Powerica's initial public offering concluded with 1.45x overall subscription, buoyed by strong institutional investor participation at 4.5x, though retail shareholders showed limited enthusiasm. The grey market premium remained marginal at ₹2 above the issue price.

Claude chatbot maker Anthropic is in early-stage discussions with major Wall Street firms for a potential IPO valued at $60 billion, with listing plans targeted for Q4 2026.

Highness Microelectronics' IPO has garnered massive investor interest with a 76.53x subscription rate. Grey market premium signals a potential 20% listing gain as institutional buyers drive strong demand.

Coal India [COALINDIA] subsidiary Central Mine is poised for its stock market listing on Monday, with grey market premium indicating positive investor sentiment ahead of the debut.

Emiac Technologies, an artificial intelligence and digital solutions firm, launched its BSE SME IPO on March 27 with a price band of ₹93-₹98 per share. Here's what investors need to know about this public offering.

Amir Chand Jagdish Kumar's ₹440 crore IPO has garnered 1.9x subscription by day three. With a price band of ₹201-₹212 and lot size of 70 shares, here's what investors should know before the final bidding day.

Tipco Engineering IPO allotment results are being finalised today. Here's a complete guide to track your allotment status, understand the current GMP, and key details investors need to know.

Sai Parenteral's IPO subscription reached 43% on Day 3 with institutional demand offsetting weak retail interest. Brokerages suggest a cautious long-term approach despite premium valuations.

Amir Chand Jagdish Kumar Exports' ₹440 crore IPO concludes with 1.63x subscription, driven by strong Non-Institutional Investor participation. Grey market premium suggests a potential listing price around ₹220.

Sai Parenterals' IPO grey market premium (GMP) indicates flat performance on day three. Investors should evaluate subscription trends and market conditions before deciding on application.

The ₹1,100 crore Powerica IPO has attracted minimal investor interest, achieving only 3% subscription by day three. With the issue set to close soon, questions loom over whether the offering can gain traction in its final day.

The Amir Chand Jagdish Kumar IPO has received 1.47x subscription by Day 3, with the issue set to close on March 27. The basmati rice and FMCG company is offering shares at ₹201-212 per unit, with listing expected on April 2.

Singapore-based DBS Group Holdings has officially launched its equity capital markets division in India, securing a landmark $1 billion IPO mandate from Manipal Health Enterprises. The move underscores growing confidence in India's capital markets among global financial institutions.

Sai Parenteral's ₹409 crore IPO struggles with minimal subscription at 0.42x by Day 2. Analysts remain cautious on valuations despite the company's parenteral drug manufacturing credentials.